Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: Implications for its effect on Kawasaki disease (KD)

Clinical and Experimental Immunology

Volumn 114, Issue 2, 1998, Pages 311-319

  Takata, Y ^a   Seki, S ^a   Dobashi, H ^a   Takeshita, S ^a   Nakatani, K ^a   Kamezawa, Y ^b   Hiraide, H ^a   Sekine, I ^a   Yoshioka, S ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Saitama College   (Japan)

Author keywords

IL 12; Interferon gamma; Kawasaki disease; Pooled human immunoglobulin; Streptococcus pyrogenic exotoxin A

Indexed keywords

DNA; EXOTOXIN; GAMMA INTERFERON; HLA DR ANTIGEN; HUMAN IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 12; RNA; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONONUCLEAR CELL; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE;

ADSORPTION; ANIMALS; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; EXOTOXINS; HUMANS; IMMUNOGLOBULINS; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-12; L CELLS (CELL LINE); LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; MICE; MUCOCUTANEOUS LYMPH NODE SYNDROME; STREPTOCOCCUS PYOGENES; SUPERANTIGENS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031731876     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00712.x     Document Type: Article

References (46)

1. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immunoglobulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325:73-80.
2. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; i:1228-30.
3. Flores G, Cunningham-Rundles C, Newland AC et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia. Am J Hematol 1993; 44:237-42.
4. Dwyer JM. Drug therapy: manipulating the immune system with immunglobulin. N Engl J Med 1992; 326:107-16.
5. Furusho K, Nakano H, Shinomiya K et al. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet 1984; ii:1055-7.
6. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous immunoglobulin. N Engl J Med 1986; 315:341-7.
7. Abe Y, Horiuchi A, Miyake M et al. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5-19.
8. Skansen-Saphir U, Andersson J, Bjork L et al. Lymphokine production induced by streptococcus pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994; 24:916-22.
9. Wolf SE, Temple PA, Kobayashi M et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146:3074-81.
10. Schoenhaut DS, Chua O, Wolitzky AG et al. Cloning and expression of murine IL-12. J Immunol 1992; 148:3433-40.
11. Brunda MJ. Interleukin-12. J Leuk Biol 1994; 55:280-8.
12. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-76.
13. Ozman L, Pericin M, Hakimi J et al. Interleukin 12, interferon γ, and tumor necrosis factor α are the key cytokines of the generalized Shwartzman reaction. J Exp Med 1994; 180:907-15.
14. Wysocka M, Kubin M, Vieira LQ et al. Interleukin-12 is required for interferon-γ, production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995; 25:672-6.
15. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994; 153:1697-706.
16. Gately MK, Warrier RR, Honasoge S et al. Administration of recombinant IL-12 to normal mice enhances the cytolytic lymphocyte activity and induces the production of interferon-gamma in vivo. Int Immunol 1994; 6:157-67.
17. Magram J, Connaughton SE, Warrior RR et al. IL-12-deficient mice are detective in IFN-γ production and type I cytokine response. Immunity 1996; 4:471-81.
18. + T cells and their IFN-γ, production in the generalized Shwartzman reaction. J Immunol 1998; 160:3522-7.
19. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 1995; 154:4333-40.
20. Kawasaki T, Kosaki F, Okawa S et al. New infantile acute febrile mucocutaneous lymph node syndrome prevailing in Japan. Pediatrics 1974; 54:271-6.
21. Kato H, Ichinose E, Yoshioka F et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982; 49:1758-66.
22. Suzuki A, Kamiya T, Kuwahara N et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986; 7:3-9.
23. Abe J, Kotzin BL, Jujo K et al. Selective expansion of T cells expressing T cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc Natl Acad Sci USA 1992; 89:4066-70.
24. Curtis N, Zheng R, Lamb JR et al. Evidence for a superantigen mediated process in Kawasaki disease. Arc Dis Child 1995; 72: 308-11.
25. Leung DYM, Meissner HC, Fulton DR et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342:1385-8.
26. Sato K, Ouchi K, Taki M. Yersinia pseudotuberculosis infection on children, resembling Izumi fever and Kawasaki disease. Pediatr Infect Dis 1983; 2:123-6.
27. Kamezawa Y, Nakahara T. Purification and characterization of streptococcal erythrogenic toxin type A produced by Streptococcus pyogenes strain NY-5 cultured in the synthetic medium NCTC-135: comparison with the dialyzed medium (TP-medium)-derived toxin. Microbiol Immunol 1989; 33:183-94.
28. Warrens AN, Heaton T, Sidhu S et al. Transfected murine cells expressing HLA class II can be used to generate alloreactive human T cells. J Immunol Methods 1994; 169:25-33.
29. + αβ T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J Immunol 1996; 156:2436-42.
30. + T cells on experimental haematogenous tumor metastases in the liver and lungs of mice. Immunology 1997; 92:561-6.
31. Gascogine NR, Ames KT. Direct binding of secreted T-cell receptor beta chain to superantigen associated with class II histocompatibility complex protein. Proc Natl Acad Sci USA 1991; 88:613-6.
32. Ma X, Chow JM, Gri G et al. The interleukin 12 p40 gene promoter is primed by interferon γ in monocytic cells. J Exp Med 1996; 183:147-57.
33. + αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 1996; 156:3366-73.
34. Satoh M, Seki S, Hashimoto W et al. Cytotoxic γδ or αβ T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 1996; 157:3886-92.
35. Heinzel FP, Schoenhaut DS, Rerko RM et al. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177:1505-9.
36. Sypek JP, Chung CL, Mayor SEH et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177:1797-802.
37. Khan IA, Matsuura T, Kasper LH. Interleukin-12 enhances murine survival against acute toxoplasmosis. Infect Immun 1994; 62:1639-42.
38. Orange JS, Wolf SF, Biron CA. Effect of IL-12 on the response and susceptibility to experimental viral infections. J Immunol 1994; 152:1253-64.
39. Anderson UG, Bjork L, Skansen-Saphir U et al. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79:211-6.
40. Matsumoto H, Suzuki K, Tsuyuguchi K et al. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG. Cytokine regulation and effect of NK cells. Infect Immun 1997; 65:4405-10.
41. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-27.
42. Leung DYM, Burns JC, Newburger JW et al. Reversal of lymphocyte activation in Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79:468-72.
43. Matsubara T, Furukuwa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interteron-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990; 56:29-36.
44. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91:602-7.
45. Leung DYM. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996; 104 (Suppl. 1):9-54.
46. Pietra BA, De Inocencio J, Giannini EH et al. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol 1994; 153:1881-8.